Our core Phase III clinical trial in liver cancer, “PHOCUS”, is progressing efficiently. In fact, we are expecting to obtain the Futility Analysis result this year. This result holds great significance as the first clinical result from PHOCUS. At the same time, this analysis shall enhance the credibility and expectations of Pexa-Vec in the global market.
This year, SillaJen was excited to have expanded the Clinical Depar...
Our core Phase III clinical trial in liver cancer, “PHOCUS”, is progressing efficiently. In fact, we are expecting to obtain the Futility Analysis result this year. This result holds great significance as the first clinical result from PHOCUS. At the same time, this analysis shall enhance the credibility and expectations of Pexa-Vec in the global market.
This year, SillaJen was excited to have expanded the Clinical Department, which will enhance our key area of focus. In order to rise to the next level, we must expand the pipeline to other tumor types.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.